Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2202CTF" target="_blank" >RIV/61988987:17110/21:A2202CTF - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61988987:17110/21:A2202CTH RIV/00843989:_____/21:E0109014 RIV/65269705:_____/21:00075849

Výsledek na webu

<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000691820800012?SID=D1v41LNKnqSuWlaZyU6" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000691820800012?SID=D1v41LNKnqSuWlaZyU6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3324/haematol.2020.267831" target="_blank" >10.3324/haematol.2020.267831</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network

Popis výsledku v původním jazyce

For many decades, international collaborative efforts have driven therapeutic advances in multiple myeloma (MM). The establishment of uniform response criteria by the International Myeloma Working Group (IMWG) has been pivotal for this progress, as adherence to strict definitions ensures data comparability between trials. An essential prerequisite for the use of uniform criteria is the application of standardized methods. Of particular interest herein is the assessment of minimal residual disease (MRD) by multiparametric flow cytometry (MFC). This has been incorporated into the IMWG response criteria since 2011 to enable better risk stratification of a growing number of patients reaching a complete remission and has the promise to be used both as a surrogate marker for overall and progression-free survival and to inform treatment decisions.1,2 However, in contrast to most routine diagnostic tests for response assessment in MM, this assay has until recently suffered from large interlaboratory variations in terms of sample processing and data acquisition, resulting in highly heterogeneous sensitivities. 3 To enable uniform and sensitive MFC MRD assessment between laboratories, EuroFlow has developed standardized operating procedures.4-6 Their next-generation flow method has been incorporated as the gold standard for MFC MRD measurements in the latest IMWG response criteria, which is expected to greatly improve data validity and comparability.7

Název v anglickém jazyce

Standardization of flow cytometric minimal residual disease assessment in international clinical trials. A feasibility study from the European Myeloma Network

Popis výsledku anglicky

For many decades, international collaborative efforts have driven therapeutic advances in multiple myeloma (MM). The establishment of uniform response criteria by the International Myeloma Working Group (IMWG) has been pivotal for this progress, as adherence to strict definitions ensures data comparability between trials. An essential prerequisite for the use of uniform criteria is the application of standardized methods. Of particular interest herein is the assessment of minimal residual disease (MRD) by multiparametric flow cytometry (MFC). This has been incorporated into the IMWG response criteria since 2011 to enable better risk stratification of a growing number of patients reaching a complete remission and has the promise to be used both as a surrogate marker for overall and progression-free survival and to inform treatment decisions.1,2 However, in contrast to most routine diagnostic tests for response assessment in MM, this assay has until recently suffered from large interlaboratory variations in terms of sample processing and data acquisition, resulting in highly heterogeneous sensitivities. 3 To enable uniform and sensitive MFC MRD assessment between laboratories, EuroFlow has developed standardized operating procedures.4-6 Their next-generation flow method has been incorporated as the gold standard for MFC MRD measurements in the latest IMWG response criteria, which is expected to greatly improve data validity and comparability.7

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

<a href="/cs/project/NV17-30089A" target="_blank" >NV17-30089A: Detailní genomická analýza zbytkových klonů mnohočetného myelomu: přístup pro individualizaci cílené terapie</a><br>

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2021

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica

ISSN

0390-6078

e-ISSN

—

Svazek periodika

106

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

4

Strana od-do

1496-1499

Kód UT WoS článku

000691820800012

EID výsledku v databázi Scopus

—